Cops Want To Look At 23andMe Customers’ DNA
By Stephanie M. Lee,
BuzzFeed
| 10. 21. 2015
Untitled Document
Individuals hoping to learn about their lineage or see how closely related they are to Neanderthals aren’t the only ones interested in the DNA tests sold by 23andMe — the FBI and other law enforcement agencies are, too.
In a transparency report published Wednesday, the direct-to-consumer genetic-testing startup revealed that law enforcement officials have requested five customers’ data over the course of the company’s nearly decade-long history. 23andMe says it hasn’t provided data in any of those cases.
“We’ve successfully fought all of those requests and we’ve had to provide no information to law enforcement,” said Kate Black — who became 23andMe’s first privacy officer in February — in an interview with BuzzFeed News. “That’s something we’re really proud of. I personally am dedicated to ensuring that we never have to give that kind of information.”
The FBI maintains its own national DNA registry of convicts and arrestees, but 23andMe has more than 1 million DNA samples (a number that may grow as the company reintroduces health-related tests), many of which aren’t already part of government registries...
Related Articles
By Grace Won, KQED [with CGS' Katie Hasson] | 12.02.2025
In the U.S., it’s illegal to edit genes in human embryos with the intention of creating a genetically engineered baby. But according to the Wall Street Journal, Bay Area startups are focused on just that. It wouldn’t be the first...
By Emma Cieslik, Ms. Magazine | 11.20.2025
Several recent Biopolitical Times posts (1, 2, 3, 4) have called attention to the alarmingly rapid commercialization of “designer baby” technologies: polygenic embryo screening (especially its use to purportedly screen for traits like intelligence), in vitro gametogenesis (lab-made eggs and sperm), and heritable genome editing (also termed embryo editing or reproductive gene editing). Those three, together with artificial wombs, have been dubbed the “Gattaca stack” by Brian Armstrong, CEO of the cryptocurrency company...
By Adam Feuerstein, Stat | 11.20.2025
The Food and Drug Administration was more than likely correct to reject Biohaven Pharmaceuticals’ treatment for spinocerebellar ataxia, a rare and debilitating neurodegenerative disease. At the very least, the decision announced Tuesday night was not a surprise to anyone paying attention. Approval...
